ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor
cells and slow the growth of kidney cancer.
PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have
recurrent or stage IV kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborators:
National Cancer Institute (NCI) University of Maryland Greenebaum Cancer Center